ArticleThe NAD+ Precursor NICOTINAMIDE RIBOSIDE (cas 1341-23-7) Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson’s Disease

Add time:09/08/2019    Source:sciencedirect.com

SummaryWhile mitochondrial dysfunction is emerging as key in Parkinson’s disease (PD), a central question remains whether mitochondria are actual disease drivers and whether boosting mitochondrial biogenesis and function ameliorates pathology. We address these questions using patient-derived induced pluripotent stem cells and Drosophila models of GBA-related PD (GBA-PD), the most common PD genetic risk. Patient neurons display stress responses, mitochondrial demise, and changes in NAD+ metabolism. NAD+ precursors have been proposed to ameliorate age-related metabolic decline and disease. We report that increasing NAD+ via the NAD+ precursor NICOTINAMIDE RIBOSIDE (cas 1341-23-7) (NR) significantly ameliorates mitochondrial function in patient neurons. Human neurons require nicotinamide phosphoribosyltransferase (NAMPT) to maintain the NAD+ pool and utilize NRK1 to synthesize NAD+ from NAD+ precursors. Remarkably, NR prevents the age-related dopaminergic neuronal loss and motor decline in fly models of GBA-PD. Our findings suggest NR as a viable clinical avenue for neuroprotection in PD and other neurodegenerative diseases.

We also recommend Trading Suppliers and Manufacturers of NICOTINAMIDE RIBOSIDE (cas 1341-23-7). Pls Click Website Link as below: cas 1341-23-7 suppliers

Prev:Research paperNICOTINAMIDE RIBOSIDE (cas 1341-23-7) attenuates alcohol induced liver injuries via activation of SirT1/PGC-1α/mitochondrial biosynthesis pathway
Next:Enantioselective reduction of 4-CHROMANONE (cas 1341-36-2) and its derivatives by selected filamentous fungi)